期刊
EMBO MOLECULAR MEDICINE
卷 12, 期 2, 页码 -出版社
WILEY
DOI: 10.15252/emmm.201910889
关键词
Mecp2; Rett; BDNF; huntingtin; axonal transport
资金
- Agence Nationale pour la Recherche [ANR-2012-BSV1-0003-03, ANR-14-CE35-0027-01, ANR-15-JPWG-0003-05, 643417]
- Fondation pour la Recherche Medicale (FRM, equipe labellisee)
- Fondation Bettencourt Schueller
- Federation pour la Recherche sur le Cerveau
- Inserm
- Aix-Marseille Universite
- AFSR
- Institut d'etablissement d'AMU Marseille Maladies Rares (MarMaRa)
- Promex Stiftung Fur Die Forschung
- Rettsyndrome.org
- NeuroCoG [ANR-15-IDEX-02]
- Agence Nationale de la Recherche (ANR) [ANR-14-CE35-0027] Funding Source: Agence Nationale de la Recherche (ANR)
Mutations in the X-linked MECP2 gene are responsible for Rett syndrome (RTT), a severe neurological disorder for which there is no treatment. Several studies have linked the loss of MeCP2 function to alterations of brain-derived neurotrophic factor (BDNF) levels, but non-specific overexpression of BDNF only partially improves the phenotype of Mecp2-deficient mice. We and others have previously shown that huntingtin (HTT) scaffolds molecular motor complexes, transports BDNF-containing vesicles, and is under-expressed in Mecp2 knockout brains. Here, we demonstrate that promoting HTT phosphorylation at Ser421, either by a phospho-mimetic mutation or inhibition of the phosphatase calcineurin, restores endogenous BDNF axonal transport in vitro in the corticostriatal pathway, increases striatal BDNF availability and synaptic connectivity in vivo, and improves the phenotype and the survival of Mecp2 knockout mice-even though treatments were initiated only after the mice had already developed symptoms. Stimulation of endogenous cellular pathways may thus be a promising approach for the treatment of RTT patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据